Cargando…

Characteristics of pachychoroid neovasculopathy

Recently, several research groups have reported a newly recognized clinical entity of choroidal neovascularization, termed pachychoroid neovasculopathy. However, its characteristics have yet to be well described. The purpose of this study was to investigate the clinical and genetic characteristics o...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagawa, Miho, Ooto, Sotaro, Yamashiro, Kenji, Tamura, Hiroshi, Oishi, Akio, Miyata, Manabu, Hata, Masayuki, Yoshikawa, Munemitsu, Yoshimura, Nagahisa, Tsujikawa, Akitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530669/
https://www.ncbi.nlm.nih.gov/pubmed/33004959
http://dx.doi.org/10.1038/s41598-020-73303-w
_version_ 1783589612986302464
author Tagawa, Miho
Ooto, Sotaro
Yamashiro, Kenji
Tamura, Hiroshi
Oishi, Akio
Miyata, Manabu
Hata, Masayuki
Yoshikawa, Munemitsu
Yoshimura, Nagahisa
Tsujikawa, Akitaka
author_facet Tagawa, Miho
Ooto, Sotaro
Yamashiro, Kenji
Tamura, Hiroshi
Oishi, Akio
Miyata, Manabu
Hata, Masayuki
Yoshikawa, Munemitsu
Yoshimura, Nagahisa
Tsujikawa, Akitaka
author_sort Tagawa, Miho
collection PubMed
description Recently, several research groups have reported a newly recognized clinical entity of choroidal neovascularization, termed pachychoroid neovasculopathy. However, its characteristics have yet to be well described. The purpose of this study was to investigate the clinical and genetic characteristics of pachychoroid neovasculopathy regardless of treatment modality. This study included 99 eyes of 99 patients with treatment-naïve pachychoroid neovasculopathy. Mean initial best-corrected visual acuity (BCVA) was 0.20 ± 0.32 logMAR, and did not change (P = 0.725) during follow-up period (mean ± SD, 37.0 ± 17.6 months). Subretinal hemorrhage (SRH) (≥ 4 disc areas in size) occurred in 20 eyes (20.2%) during follow-up. Age, initial BCVA, central retinal thickness, SRH (≥ 4 disc areas in size) and treatment (aflibercept monotherapy) were significantly associated with the final BCVA (P = 0.024, < 0.001, 0.031, < 0.001, and 0.029, respectively). Multiple regression analysis showed initial BCVA and presence of SRH to be significant predictors of final BCVA (both P < 0.001). Polypoidal lesions were more common in the SRH group than in the non-SRH group (85.0% vs 48.1%, P = 0.004). There was no significant difference in the frequency of the risk allele in ARMS2 A69S, CFH I62V, CFH Y402H between these groups (P = 0.42, 0.77, and 0.85, respectively). SRH (29.1% vs 9.1%, P = 0.014) and choroidal vascular hyperpermiability (65.5% vs 43.2%, P = 0.027) were seen more frequently in the polypoidal lesion (+) group than in the polypoidal lesion (−) group. There was considerable variation in lesion size and visual function in patients with pachychoroid neovasculopathy, and initial BCVA and presence of SRH at the initial visit or during the follow-up period were significant predictors of final BCVA.
format Online
Article
Text
id pubmed-7530669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-75306692020-10-02 Characteristics of pachychoroid neovasculopathy Tagawa, Miho Ooto, Sotaro Yamashiro, Kenji Tamura, Hiroshi Oishi, Akio Miyata, Manabu Hata, Masayuki Yoshikawa, Munemitsu Yoshimura, Nagahisa Tsujikawa, Akitaka Sci Rep Article Recently, several research groups have reported a newly recognized clinical entity of choroidal neovascularization, termed pachychoroid neovasculopathy. However, its characteristics have yet to be well described. The purpose of this study was to investigate the clinical and genetic characteristics of pachychoroid neovasculopathy regardless of treatment modality. This study included 99 eyes of 99 patients with treatment-naïve pachychoroid neovasculopathy. Mean initial best-corrected visual acuity (BCVA) was 0.20 ± 0.32 logMAR, and did not change (P = 0.725) during follow-up period (mean ± SD, 37.0 ± 17.6 months). Subretinal hemorrhage (SRH) (≥ 4 disc areas in size) occurred in 20 eyes (20.2%) during follow-up. Age, initial BCVA, central retinal thickness, SRH (≥ 4 disc areas in size) and treatment (aflibercept monotherapy) were significantly associated with the final BCVA (P = 0.024, < 0.001, 0.031, < 0.001, and 0.029, respectively). Multiple regression analysis showed initial BCVA and presence of SRH to be significant predictors of final BCVA (both P < 0.001). Polypoidal lesions were more common in the SRH group than in the non-SRH group (85.0% vs 48.1%, P = 0.004). There was no significant difference in the frequency of the risk allele in ARMS2 A69S, CFH I62V, CFH Y402H between these groups (P = 0.42, 0.77, and 0.85, respectively). SRH (29.1% vs 9.1%, P = 0.014) and choroidal vascular hyperpermiability (65.5% vs 43.2%, P = 0.027) were seen more frequently in the polypoidal lesion (+) group than in the polypoidal lesion (−) group. There was considerable variation in lesion size and visual function in patients with pachychoroid neovasculopathy, and initial BCVA and presence of SRH at the initial visit or during the follow-up period were significant predictors of final BCVA. Nature Publishing Group UK 2020-10-01 /pmc/articles/PMC7530669/ /pubmed/33004959 http://dx.doi.org/10.1038/s41598-020-73303-w Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Tagawa, Miho
Ooto, Sotaro
Yamashiro, Kenji
Tamura, Hiroshi
Oishi, Akio
Miyata, Manabu
Hata, Masayuki
Yoshikawa, Munemitsu
Yoshimura, Nagahisa
Tsujikawa, Akitaka
Characteristics of pachychoroid neovasculopathy
title Characteristics of pachychoroid neovasculopathy
title_full Characteristics of pachychoroid neovasculopathy
title_fullStr Characteristics of pachychoroid neovasculopathy
title_full_unstemmed Characteristics of pachychoroid neovasculopathy
title_short Characteristics of pachychoroid neovasculopathy
title_sort characteristics of pachychoroid neovasculopathy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530669/
https://www.ncbi.nlm.nih.gov/pubmed/33004959
http://dx.doi.org/10.1038/s41598-020-73303-w
work_keys_str_mv AT tagawamiho characteristicsofpachychoroidneovasculopathy
AT ootosotaro characteristicsofpachychoroidneovasculopathy
AT yamashirokenji characteristicsofpachychoroidneovasculopathy
AT tamurahiroshi characteristicsofpachychoroidneovasculopathy
AT oishiakio characteristicsofpachychoroidneovasculopathy
AT miyatamanabu characteristicsofpachychoroidneovasculopathy
AT hatamasayuki characteristicsofpachychoroidneovasculopathy
AT yoshikawamunemitsu characteristicsofpachychoroidneovasculopathy
AT yoshimuranagahisa characteristicsofpachychoroidneovasculopathy
AT tsujikawaakitaka characteristicsofpachychoroidneovasculopathy